Mantle cell lymphoma is an aggressive B-cell malignancy. Current frontline chemoimmunotherapies produce high response rates but relapse inevitable. Furthermore, the elderly and those with comorbidities are precluded from standard regimens stem transplant, leaving them limited options. Targeted therapies, including Bruton tyrosine kinase inhibitors, effective treatment strategy in mantle lymphom...

1. Hansen SV, Nyvold CG, MH. Mantle cell lymphoma and the evidenceof an immature lymphoid component. Leuk Res. 2022;115:106824. doi: 10.1016/j.leukres.2022.106824. CrossRef Google Scholar

BACKGROUND Malignant lymphomas are classified on the basis of morphology, immunohistochemistry, and genetic and molecular biological features. Morphology is considered the most important and basic feature. Lymphomas can be classified as small, medium, or large depending on the cell size, but this criterion tends to be rather subjective. The aim of this study was to investigate the usefulness of...

The determination of prognosis for B-Non-Hodgkin's lymphoma (NHL) is known to be related to the multiple differences in tumor cell biology. Bcl-2 and Bcl-6 are two markers linked to germinal center B cells. Both markers are thought to have an effect on prognosis of mature B-cell neoplasms. Forty-four patients with chronic B-cell neoplasm were included; Bcl-2 and Bcl-6 expression by immunohistoc...

BACKGROUND The genetic hallmark of mantle cell lymphoma is a t(11;14)(q13;q32). However, additional genomic alterations are likely involved in the pathogenesis of this lymphoma. DESIGN AND METHODS To determine the incidence and clinical relevance of these aberrations, we analyzed 103 well-characterized samples of mantle cell lymphoma by fluorescence in situ hybridization for the most common r...

The guideline group was selected to be representative of UKbased medical experts and patients representatives. Ovid MEDLINE, EMBASE and NCBI Pubmed were searched systematically for publications in English from 1980 to 2011 using the MeSH subheading ‘lymphoma, mantle cell’ and ‘lymphoma, mantle cell’ as a keyword, as well as all subheadings. In addition, all references to mantle cell lymphoma in...

PURPOSE Additional targeted therapeutics are needed for the treatment of lymphoma. Abexinostat is an oral pan-histone deacetylase inhibitor (HDACi) displaying potent activity in preclinical models. We conducted a multicenter phase I/II study (N = 55) with single-agent abexinostat in relapsed/refractory lymphoma. EXPERIMENTAL DESIGN In phase I, 25 heavily pretreated patients with any lymphoma ...

The finding of umbilical metastasis has historically been called a "Sister Mary Joseph Nodule". A few case reports of lymphoma presenting in this manner have been documented. We report a case of relapsed mantle cell lymphoma (MCL) presenting as a Sister Mary Joseph's nodule. Although the few reports of lymphoma exhibiting umbilical metastasis suggest that patients may still expect a reasonable ...

Uses : = Low-grade or follicular CD20-positive non-Hodgkin’s lymphoma = Follicular CD20-positive non-Hodgkin's lymphoma = Low-grade or follicular CD20-positive non-Hodgkin’s lymphoma = CD20-positive diffuse large B-cell non-Hodgkin’s lymphoma = CD20-positive chronic lymphocytic leukemia, Mantle cell lymphoma. = Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Po...

BACKGROUND Addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy (R-chemo) has been shown to improve response rates and progression-free survival in patients with indolent or mantle cell lymphoma. However, the impact of R-chemo on overall survival is unclear. We performed a comprehensive systematic review and meta-analysis to examine the efficacy of combined immunochemotherapy...